Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) has announced an exclusive marketing promotion service agreement with Grand Life Sciences Co., Ltd., aimed at advancing the commercialization of Zelgen’s recombinant human thrombin product in Greater China.
Under the terms of the agreement, Grand Life will serve as the sole marketing promotion service provider for Zelgen’s recombinant human thrombin. The partnership includes an upfront payment of RMB 260 million (USD 36 million) from Grand Life, followed by RMB 140 million (USD 19.5 million) in the first year of commercialization. Additionally, Grand Life could earn up to RMB 915 million (USD 127.8 million) in sales-based milestone payments. Zelgen will handle the marketing promotion fees.
Recombinant human thrombin, a highly specific human serine protease, is developed from Zelgen’s advanced recombinant protein and antibody new drug technology platforms. It is recognized as the only recombinant human thrombin produced using gene technology in China, having demonstrated successful results in Phase III clinical trials. The product is currently being prepared for a market approval filing in China.- Flcube.com
